Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 7/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 7/20 | 1.00 |
| ▸ | F3 | P13726 | 3/20 | 1.00 |
| ▸ | PNLIP | P16233 | 1/20 | 1.00 |
| ▸ | NOS2 | P35228 | 1/20 | 1.00 |
| ▸ | CES1 | P23141 | 4/20 | 0.76 |
| ▸ | CES2 | O00748 | 2/20 | 0.76 |
| ▸ | RELA | Q04206 | 3/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.71 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.71 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.71 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.71 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.71 |
| ▸ | PTPRC | P08575 | 2/20 | 0.71 |
| ▸ | PTPRF | P10586 | 2/20 | 0.71 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.71 |
| ▸ | ACP1 | P24666 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oleanonic Acid SCHEMBL18687844 | 1.00 | PTPN2 (1.00) | PTPN2PTPN1F3PNLIPNOS2 | |
| Oleanonic Acid SCHEMBL18688313 | 1.00 | PTPN2 (1.00) | PTPN2PTPN1F3PNLIPNOS2 | |
| Oleanonic Acid SCHEMBL2762433 | 1.00 | PTPN2 (1.00) | PTPN2PTPN1F3PNLIPNOS2 | |
| Oleanonic Acid SCHEMBL16175546 | 1.00 | PTPN2 (1.00) | PTPN2PTPN1F3PNLIPNOS2 | |
| Oleanonic Acid SCHEMBL12337276 | 1.00 | PTPN2 (1.00) | PTPN2PTPN1F3PNLIPNOS2 | |
| Oleanonic Acid SCHEMBL246220 | 1.00 | PTPN2 (1.00) | PTPN2PTPN1F3PNLIPNOS2 | |
| Oleanonic Acid SCHEMBL6898284 | 1.00 | PTPN2 (1.00) | PTPN2PTPN1F3PNLIPNOS2 | |
| Oleanonic Acid SCHEMBL12313105 | 1.00 | PTPN2 (1.00) | PTPN2PTPN1F3PNLIPNOS2 | |
| SCHEMBL17166004 | 0.92 | PTPN1 (0.85) | PTPN2PTPN1F3PNLIPNOS2 | |
| SCHEMBL16152971 | 0.89 | PTPN1 (0.81) | PTPN2PTPN1F3PNLIPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278913-B2 | Therapeutic compounds and methods of use | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140275618-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2014-09-18 | — | — | US | disclosed |
| US-8034955-B2 | triterpenoids such as 2-cyano-3,12-dioxoolean-1,9-dien-28oic acid, used for inhibiting gamma -inteferon-induced nitric oxide production in macrophages; preventing cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034955-B2 | triterpenoids such as 2-cyano-3,12-dioxoolean-1,9-dien-28oic acid, used for inhibiting gamma -inteferon-induced nitric oxide production in macrophages; preventing cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2011-10-11 | — | — | US | disclosed |
| US-7863327-B2 | Therapeutic compounds and methods of use | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080220057-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080220057-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275618-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | PARK7, MGMT, SNCA | PTPN2 4769/4885PTPN1 4812/4885F3 4764/4885 |
| US-20080220057-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | PARK7, MGMT, SNCA | PTPN2 4769/4885PTPN1 4812/4885F3 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.